TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT02013167

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Standard of Care Chemotherapy
Description: * FLAG (fludarabine, cytarabine arabinoside, and granulocyte colony-stimulating factor) ± anthracycline-based regimen (e.g. idarubicin 10 mg/m² days 1 \& 3; fludarabine 30 mg/m² days 1-5; cytarabine arabinoside 2 g/m² days 1-5). Patients \> 60 years: Idarubicin 5 mg/m² day 1 \& 3; fludarabine 20 mg/m² day 1-5; cytarabine arabinoside 1 g/m² day 1-5~* HiDAC (high-dose cytarabine arabinoside) - based regimen ≥1 g/m²/day ± anthracycline and/or in combination with other drugs such as native Escherichia coli asparaginase, polyethylene glycol linked to asparaginase (PEG-asparaginase), vinca alkaloids, steroids, etoposide or alkylating agents~* High-dose methotrexate-based regimen (HDMTX; 500 mg/m² to 3 g/m² infused up to 24 hours) in combination with native E. coli asparaginase, PEG-asparaginase, vinca alkaloids, steroids, etoposide or alkylating agents.~* Clofarabine as a single agent as recommended in the prescribing information or clofarabine-based regimens with 20 mg/m²/day for up to 5 days.
Study: NCT02453958

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Multi-modal assessment system
Description: Subjects were assessed using a multi-modal concussion assessment battery incorporating eye-tracking, balance, and neurocognitive tests

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Multi-modal assessment system
Description: Subjects were assessed using a multi-modal concussion assessment battery incorporating eye-tracking, balance, and neurocognitive tests
Study: NCT02111499

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: LAS41004 IMP3
Description: daily topical application

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: LAS41004 IMP3
Description: daily topical application

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LAS41004 IMP4
Description: daily topical application

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LAS41004 IMP4
Description: daily topical application

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LAS41004 IMP4
Description: daily topical application

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LAS41004 IMP4
Description: daily topical application

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: LAS41004 IMP4
Description: daily topical application

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: LAS41004 IMP4
Description: daily topical application

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LAS41004 IMP6
Description: daily topical application

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LAS41004 IMP6
Description: daily topical application

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LAS41004 IMP6
Description: daily topical application

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LAS41004 IMP6
Description: daily topical application

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: LAS41004 IMP6
Description: daily topical application

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: LAS41004 IMP6
Description: daily topical application

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LAS41004 IMP5
Description: once daily, topical

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LAS41004 IMP5
Description: once daily, topical

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LAS41004 IMP5
Description: once daily, topical

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LAS41004 IMP5
Description: once daily, topical

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: LAS41004 IMP5
Description: once daily, topical

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: LAS41004 IMP5
Description: once daily, topical
Study: NCT01852175

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Prasugrel
Description: Prasugrel 60mg loading dose and 10mg maintenance dose

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ticagrelor
Description: Ticagrelor 180mg loading dose and 90mg bid maintenance dose
Study: NCT02035345

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Study: NCT01364389

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AIN457
Description: 3 mg/kg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ACZ885
Description: 3 mg/kg
Study: NCT06281041

Intervention type: DRUG
Intervention: Antiplatelet Agents
Description: Aspirin or clopidogrel
Study: NCT03397082

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lidocaine gel
Description: 5mL of lidocaine gel applied topically to cervix previous to clamping and paracervical blockade.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 5mL of sterile gel applied topically to cervix previous to clamping and paracervical blockade.
Study: NCT01364389

Intervention type: DRUG
Group type: OTHER
Intervention: Prednisone
Description: 20 mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Matching placebo to AIN457, ACZ885 and prednisone

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Matching placebo to AIN457, ACZ885 and prednisone

Intervention type: DRUG
Group type: OTHER
Intervention: Placebo
Description: Matching placebo to AIN457, ACZ885 and prednisone
Study: NCT01975597

Intervention type: PROCEDURE
Intervention: Bone marrow aspirates and biopsy
Study: NCT02568592

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: High Fat
Description: High Fat - Carbohydrate (20%), Fat (65%), Protein (15%)

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Normal
Description: Normal - Carbohydrate (50%), Fat (35%) and Protein (15%)

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Normal + Extra Fat
Description: Normal + Extra Fat - Carbohydrate (50%), Fat (65%), Protein (15%). Carbohydrate and protein intake identical in absolute amounts to NORMAL, with an additional 30% extra energy coming from fat.
Study: NCT03362372

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mediterranean diet counseling
Description: The participants of the intervention CAP will enter into an educational program to increase adherence to the DiMet that will integrate three operational components:~1. Explain the particularities of DiMet and the benefits of its monitoring. It will be an individual visit of 25-30 minutes (V1) where the study variables will be collected and the medical tests will be performed and repeated annually for two years (V3 and V5).~2. Clarify the doubts of the DiMet monitoring and the advice received. It will be a telephone visit to reinforce the intervention, with annual frequency, for two years (V2 and V4).~3. Report on DiMet's own foods, cooking habits, adapted recipes and other related topics. It will be for access to an ad hoc designed nutrition blog.
Study: NCT03337282

Intervention type: PROCEDURE
Intervention: Protocolized general anesthesia
Description: Induction and maintenance of general anesthesia, post-operative analgesia with protocolized drugs and doses. Maintenance of MAP +/- 20% of baseline with vasopressors as needed.
Study: NCT03200899

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: MAPSS-MS
Description: MAPSS-MS is a computer-assisted cognitive rehabilitation intervention. It is a combination of home computer training and 8-weeks of group sessions on lifestyle change and compensatory cognitive strategies.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Usual Care plus computer games
Description: Participants assigned to this arm receive their usual medical care and referral to the My Brain Games website.
Study: NCT04457609

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Oseltamivir
Description: Current standardized treatment for Covid-19

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oseltamivir
Description: Current standardized treatment for Covid-19
Study: NCT02067962

Intervention type: BIOLOGICAL
Group type: OTHER
Intervention: Blood sample
Description: Blood sample
Study: NCT00980460

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fluorouracil
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Irinotecan Hydrochloride
Description: Given IV
Study: NCT02642380

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone (4 cycles)
Description: dexamethasone 40mg daily for 4 consecutive days every 14 days for 4 courses

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexamethasone (1 cycle)
Description: dexamethasone 40mg daily for 4 consecutive days
Study: NCT01019369

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Medroxyprogesterone 17-Acetate
Description: Depot medroxyprogesterone acetate, SC, every 12 weeks for 1 year

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Medroxyprogesterone 17-Acetate
Description: Depot medroxyprogesterone acetate, SC, every 12 weeks for 1 year
Study: NCT00753363

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Weight Loss
Description: 6 months of weight loss

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Aerobic Exercise Training
Description: 6 months of aerobic exercise training
Study: NCT03934853

Intervention type: DEVICE
Group type: OTHER
Intervention: Dynamic Dental Navigation
Description: Aid in dental implant placement in humans
Study: NCT00888342

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: supplementary oxygen
Description: Supplementary oxygen 2 L/min if SpO2 \< 90%. If SpO2 \< 90 % the oxygen dose is titrated until SpO2 reads 88-92%. For patients on LTOT the oxygen dose is doubled for intervention.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: zopiclone
Description: 5 mg sedative given approximately 1 hour before sleep

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: alcohol
Description: 5 mg alcohol/kg body-weight approximately 1 hour before sleep
Study: NCT00392990

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Regimen A
Description: Cyclophosphamide (800 mg/m2 IV over 1 hour)+ vincristine (1.5 mg/m2 IV PUSH)+ doxorubicin (40 mg/m2 IV)+ high-dose methotrexate (2,700 mg/m2 IV over 23 hours)+ rituximab (500 mg/m2 IV)(R-CODOX-M) regimen

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Regimen B
Description: Rituximab (500 mg/m2 IV once)+ Ifosfamide (1500 mg/m2 IV daily over 3 hours)+ Etoposide (60 mg/m2 IV daily over 1 hour), and Cytarabine (2 grams/m2 IV over 3 hours for 4 doses)
Study: NCT00241904

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Lifestyle Changes
Description: Nutrition counseling, smoking cessation counseling, medication compliance counseling, exercise

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Lifestyle Changes
Description: Nutrition counseling, smoking cessation counseling, medication compliance counseling, exercise

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Antiplatelet Agents
Description: Aspirin 81 mg q day

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Beta Blocker
Description: Oral medication

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ACE Inhibitors
Description: Oral medications, received 1-2 times per day
Study: NCT03441230

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Balloon characteristics
Description: Different size balloon

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Balloon characteristics
Description: Different size balloon

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Balloon characteristics
Description: Different size balloon

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Balloon characteristics
Description: Different size balloon

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Balloon characteristics
Description: Different size balloon

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Balloon characteristics
Description: Different size balloon

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Balloon characteristics
Description: Different size balloon

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Balloon characteristics
Description: Different size balloon

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Balloon characteristics
Description: Different size balloon

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Balloon characteristics
Description: Different size balloon
Study: NCT01337544

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: HAPLOIDENTICAL IL-15 STIMULATED NK CELLS
Description: ONE MEGADOSE 30 DAYS AFTER TRANSPLANTATION (DOSE WILL DEPEND ON PATIENT BODY WEIGHT)
Study: NCT02422849

Intervention type: OTHER
Group type: OTHER
Intervention: hospital specialist

Intervention type: OTHER
Group type: OTHER
Intervention: General Practitioner
Study: NCT03576911

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Coenzyme Q10

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT02401984

Intervention type: OTHER
Intervention: Screening
Description: Participants will fill out a short screening questionnaire where different aspects of mental health and behavioral problems will be assessed.
Study: NCT00980460

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Irinotecan Hydrochloride
Description: Given IV

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies
Study: NCT02020408

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: [11C]raclopride
Description: 1.\[11C\]raclopride -The change (Δ) in BPND (the difference between the \[11C\]raclopride BPND at baseline and post-AMPH treatment normalized to the baseline BPND

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: [11C]DASB
Description: BPND of \[11C\]DASB.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: amphetamine
Description: The change (Δ) in BPND (the difference between the \[11C\]raclopride BPND at baseline and post-AMPH treatment normalized to the baseline BPND.
Study: NCT03479710

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: FMT infusion
Description: Fecal microbiota transplantation via OGD
Study: NCT01961063

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: busulfan
Description: Given IV

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: lentivirus vector rHIV7-shI-TAR-CCR5RZ-transduced hematopoietic progenitor cells
Description: Given IV

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: pharmacological study
Description: Correlative studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis
Description: Correlative studies
Study: NCT00258934

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Inactivated, split-virion influenza vaccine
Description: 0.1 mL single annual dose

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Inactivated, split-virion, influenza virus
Description: 0.5 mL single annual dose
Study: NCT01631396

Intervention type: DRUG
Intervention: Sugammadex vs. Neostigmine
Description: * Sugammadex Group (n=20) - anesthesia induced by Rocuronium 0.4mg/kg body, additional Rocuronium 0.1-0.2 mg/kg body as needed during surgery (not more than x2), muscular blockage reversal using Sugammadex 2.0 mg/kg body.~* Neostigmine Group (n=20) - anesthesia induced by Rocuronium 0.4mg/kg body, additional Rocuronium 0.1-0.2 mg/kg body as needed during surgery (not more than x2), muscular blockage reversal using Neostigmine 0.05 mg/kg body and atropine 0.1 mg/kg body.

Intervention type: DRUG
Intervention: Sugammadex vs. Neostigmine
Description: * Sugammadex Group (n=20) - anesthesia induced by Rocuronium 0.4mg/kg body, additional Rocuronium 0.1-0.2 mg/kg body as needed during surgery (not more than x2), muscular blockage reversal using Sugammadex 2.0 mg/kg body.~* Neostigmine Group (n=20) - anesthesia induced by Rocuronium 0.4mg/kg body, additional Rocuronium 0.1-0.2 mg/kg body as needed during surgery (not more than x2), muscular blockage reversal using Neostigmine 0.05 mg/kg body and atropine 0.1 mg/kg body.
Study: NCT01616368

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mindful Eating and Living Course
Description: An eight week course designed to teach mindfulness skills with an emphasis on mindful eating.
Study: NCT01925248

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Whey protein
Description: Whey protein group participants will take supplement drinks that contain whey protein, daily before breakfast and before dinner for 3 months.

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo group
Description: Placebo group participants will take supplement drinks that do not contain whey protein, daily before breakfast and before dinner for 3 months.
Study: NCT02620488

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Guided Imagery
Description: Brief guided imagery session with a trained clinician focused on relaxation and pleasant imagery.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Guided Imagery
Description: Brief guided imagery session with a trained clinician focused on relaxation and pleasant imagery.
Study: NCT03347084

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Excitation
Description: Administration of LIFUP, a method of deep brain stimulation, according to excitation paradigms using the following parameters: Tone Burst Duration = 50ms; Pulse Repetition Frequency = 10Hz; ISPTA = 720 mW/cm2. Four treatments of thirty seconds each, with two-minute intervals between treatment (20 minutes, approximately)
Study: NCT00147316

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Alteplase
Description: 0.6mg/kg intravenous alteplase with 10% being administered as a bolus followed by continuous infusion of the remainder over 1 hour
Study: NCT02978950

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Duplex ultrasound surveillance
Description: bilateral lower extremity venous duplex

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: No ultrasound surveillance
Description: will have daily exam and history as per normal clinical routine
Study: NCT02646813

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Intraluminal Placement
Description: Pt. will have Arndt Endobronchial Blocker placed intraluminally
Study: NCT00980460

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Liver Transplantation
Description: Undergo liver transplant

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Liver Transplantation
Description: Undergo liver transplant
Study: NCT00311597

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Radiosurgery
Description: single fractionated radiation therapy
Study: NCT00398866

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Synvisc (Hylan G-F20; hyaluronan injection)
Description: 1 ml of hyaluronan (Synvisc) injected once a week for 2 consecutive weeks

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bupivicaine (local anesthesia injection)
Description: 1 ml of bupivicaine 0.5% injected once a week for 2 weeks
Study: NCT00980460

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Temsirolimus
Description: Given IV

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Therapeutic Conventional Surgery
Description: Undergo surgery

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Therapeutic Conventional Surgery
Description: Undergo surgery

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Therapeutic Conventional Surgery
Description: Undergo surgery

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Therapeutic Conventional Surgery
Description: Undergo surgery

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Therapeutic Conventional Surgery
Description: Undergo surgery

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vincristine Sulfate
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vincristine Sulfate
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vincristine Sulfate
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vincristine Sulfate
Description: Given IV
Study: NCT03347084

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Inhibition
Description: Administration of LIFUP, a method of deep brain stimulation, according to inhibition paradigms using the following parameters: Tone Burst Duration = 50ms and Pulse Repetition Frequency = 10Hz. Four treatments of thirty seconds each, with two-minute intervals between treatment (20 minutes, approximately)
Study: NCT03443921

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Artery Divestment Technique
Description: Tunica adventitia was pick up by forceps and opened by electrocoagulation at 1 cm distal from tumor-artery contact. Space between tunica adventitia and external elastic lamina (EEL) were blunt lifting tumor-invaded adventitia by angled clamp. Adventitia was then sectioned to show EEL. Loose dissect space could be achieve along long the plane between EEL and adventitia as long as tumor invasion outside EEL. Tumor and invaded adventitia were further cut open by electrocoagulation proximally. Circumferentially, separation could be done by blunt dissection around EEL. Nourishing blood vessels of the artery would be secured by electrocoagulation or ultrasonic scalpel while major branch would be ligated or transfixed.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Nab-paclitaxel
Description: After eligibility testing as blood tests, contrast-enhanced CT and MRI scan, 3 cycles were administered (1,000 mg/m2 of gemcitabine and 125 mg/m2 of nab-paclitaxel on days 1, 8, and 15 every 28 days).Patients will be reevaluated and curative operation would be attempted if without disease progression.
Study: NCT00398866

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Kenalog (triamcinolone; corticosteroid injection)
Description: 1 ml (40mg) of triamcinolone (Kenalog) injected the first week, followed by a placebo injection of 1 ml 0.5% bupivacaine the second week; Kenalog is a non-suspension steroid preparation and is less likely to cause post-injection flares than a suspension preparation
Study: NCT02646813

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Extraluminal Placement
Description: Pt. will have Arndt Endobronchial Blocker placed extraluminally